DuPont gets Gates grant for protein drug production platform

By Gareth Macdonald contact

- Last updated on GMT

iStock/markusblanke
iStock/markusblanke

Related tags: Bill & melinda gates foundation

DuPont has joined a Gates Foundation backed effort to develop low cost production methods for therapeutic proteins.

The Bill & Melinda Gates Foundation awarded the firm’s DuPont Industrial Biosciences division a grant to support development of production systems for protein-based medicines, with a particular focus on scalable manufacturing platforms.

Division president William F. Feehery said: “We cannot underestimate the complexity of this challenge. At the same time, we cannot turn our backs on the possibility of improving access and affordability of life-saving medications for communities around the world.

This is cutting-edge science. We are honoured to work with a leading organization like The Gates Foundation to tackle this type of issue, as no one company or entity can get there on their own​.”

DuPont is one of a number of companies the Gates Foundation has tasked with lowering the cost of making large molecule drugs.

Last week, the Foundation granted Belgian technology firm Univercells - and consortium partners Batavia Biosciences and Natrix Separations - $12m (€12.5m) to develop a vaccine production platform.

DuPont is due to merge with Dow Chemical under a deal announced in late 2015.

Previously the aim was to complete the merger by the end of this year. However, in October the firms said completion would likely be delayed until early 2017​.

Related news

Related products

show more

INNOBIO® Vegan EAAs Enhanced with Vegan CLA

INNOBIO® Vegan EAAs Enhanced with Vegan CLA

INNOBIO Limited | 19-Aug-2019 | Technical / White Paper

It is known to all that EAAs can improve muscle growth and exercise performance, as well as increase lean body mass and prevent muscle loss. INNOBIO® EAAs...

Fermented Soy for Natural Digestive Support

Fermented Soy for Natural Digestive Support

Lallemand Bio-Ingredients | 22-Apr-2019 | Technical / White Paper

Lallemand is running a new clinical trial for Gastro-AD® in spring 2019. Gastro-AD® is a clinically studied food supplement based on non-GMO soy fermented...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars